{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-031478","form_type":"8-K","ticker":"INAB","cik":"0001740279","company_name":"IN8BIO, INC.","filed_at":"2024-03-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.361266+00:00","generated_at":"2026-06-04T19:54:45.327225+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"IN8bio reports Q4 2023 net loss of $7.6M and cash of $21.3M; highlights positive clinical data","bullets":["Q4 2023 net loss $7.6M ($0.22 per share) vs Q4 2022 net loss $7.8M ($0.32 per share).","Full-year 2023 net loss $30.0M ($1.00 per share); R&D expenses increased to $16.8M.","Cash $21.3M as of Dec 31, 2023 vs $18.2M a year earlier; private placement extended runway into 1Q 2025.","100% of evaluable leukemia patients (n=10) in INB-100 Phase 1 remained in remission as of Nov 3, 2023.","Appointed Dr. Corinne Epperly, M.D., M.P.H. to Board of Directors."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-031478","json":"https://secwatch.observer/filing/0000950170-24-031478.json","markdown":"https://secwatch.observer/filing/0000950170-24-031478.md","text":"https://secwatch.observer/filing/0000950170-24-031478.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1740279/000095017024031478/0000950170-24-031478-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1740279/000095017024031478/inab-20240314.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T19:54:45.327225+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f3350a7f26522d0c78f6e09ae2c2f0621d6ab0d5","claim":"IN8BIO, INC. reported the fourth quarter and fiscal year ended December 31, 2023 results: net income a net loss of $7.6 million, or $0.22 per basic and diluted common share, for the three months ended December 31, 2023, EPS $0.22 per basic and diluted common share.","evidence_excerpt":"IN8bio, Inc. issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1740279/000095017024031478/0000950170-24-031478-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and fiscal year ended December 31, 2023"},{"label":"Net income","value":"a net loss of $7.6 million, or $0.22 per basic and diluted common share, for the three months ended December 31, 2023"},{"label":"EPS","value":"$0.22 per basic and diluted common share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}